Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...1617181920212223242526...123124»
  • ||||||||||  Real-world comparison of first-line treatments for metastatic clear cell renal cell carcinoma (mccRCC) (Section 38) -  Mar 5, 2024 - Abstract #AACR2024AACR_3122;    
    Clinical trials have compared these regimens to sunitinib, with no direct comparison between them...Regimens included IO/IO (ipilimumab/nivolumab [I/N]) or IO/TKI (pembrolizumab/axitinib [P/A], nivolumab/cabozantinib [N/C], or pembrolizumab/lenvatinib [P/L])...Genomic characteristics will be reported in poster.Despite small sample size, our real-world data showed that patients treated with IO/IO had significantly worse outcomes compared to those treated with IO/TKI. While this difference may stem from a more aggressive disease in IO/IO group but further insights needs to be obtained through future prospective studies comparing IO/IO and IO/TKI regimens.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enhancing radiotherapy with lenvatinib by targeting the CXCL13/CXCR5/NF-?B axis (Section 28) -  Mar 5, 2024 - Abstract #AACR2024AACR_2667;    
    Immunohistochemistry (IHC) staining of tumor tissue also revealed an upregulation of apoptosis-related proteins and the downregulation of CXCL13/CXCR5/NF-?B related proteins. In conclusion, our findings suggest that Lenvatinib can serve as a radiosensitizer, enhancing the sensitivity of NSCLC patients to radiotherapy by targeting the CXCL13/CXCR5/NF-?B signaling pathway.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal:  Differentiated thyroid carcinoma: what the nonspecialists needs to know. (Pubmed Central) -  Mar 5, 2024   
    One of the overarching goals in the management of DTC is the need to personalize treatment by tailoring its modality and intensity according to ongoing prognostic stratification, evolving knowledge about the disease, and patient characteristics and preference. In metastatic disease that is refractory to radioactive iodine, thyroid tumors are being reclassified into molecular subtypes that better reflect their biological properties and for which molecular alterations can be targeted with specific agents.
  • ||||||||||  PRT811 / Prelude Therap, Lenvima (lenvatinib) / Eisai, Merck (MSD), PRT543 / Prelude Therap
    PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands (Grand Ballroom GHIJ) -  Mar 5, 2024 - Abstract #AHNSCOSM2024AHNS_COSM_59;    
    Identifying PRMT5 as a putative candidate, we next determined the applicability of PRMT5 inhibitors (PRT543 and PRT811) using ACC cell lines, organoids, and patient derived xenograft (PDX) models. Our study underscores the role of PRMT5 in ACC and supports PRMT5 blockade as a promising strategy for treating this rare disease.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer (clinicaltrials.gov) -  Mar 5, 2024   
    P=N/A,  N=23, Completed, 
    Our study underscores the role of PRMT5 in ACC and supports PRMT5 blockade as a promising strategy for treating this rare disease. Active, not recruiting --> Completed | Trial completion date: Nov 2023 --> Mar 2024 | Trial primary completion date: Nov 2023 --> Mar 2024
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Journal, Metastases:  Systemic Chemotherapy for Advanced Hepatocellular Carcinoma in Patients With Child-Pugh class B. (Pubmed Central) -  Mar 4, 2024   
    OS and response rates were similar across systemic chemotherapies. Prognosis for HCC in Child-Pugh class B patients was associated with liver function, necessitating further research for optimal treatment.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Significance of Continuous Low-Dose Lenvatinib for the Treating of the Patients with Unresectable Thyroid Carcinoma. (Pubmed Central) -  Mar 4, 2024   
    The cumulative dose of lenvatinib administered tended to be higher in the patients treated with low doses (< 8 mg/day) than in the patients treated with relatively high doses (8-24 mg/day). Considering its adverse events, the continuation of lenvatinib treatment with an adequate daily dose and drug interruption may help prolong the survival of patients with unresectable thyroid carcinoma.
  • ||||||||||  Review, Journal:  The VEGFs/VEGFRs system in Alzheimer's and Parkinson's diseases: pathophysiological roles and therapeutic implications. (Pubmed Central) -  Mar 4, 2024   
    Specific VEGFRs targeting, aimed at selective VEGFR-1 inhibition, while preserving VEGFR-2 signal transduction, appears as a promising strategy to hit the molecular mechanisms underlying AD pathology. Moreover, therapeutic VEGF-based approaches can be proposed for PD treatment, with the aim of fine-tuning its brain levels to amplify its neurotrophic/neuroprotective effects while limiting an excessive impact on vascular permeability.
  • ||||||||||  EG-007 / Evergreen Therap
    Trial completion date, Trial primary completion date:  Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem (clinicaltrials.gov) -  Mar 2, 2024   
    P2,  N=28, Not yet recruiting, 
    Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025 Trial completion date: Jul 2024 --> Oct 2025 | Trial primary completion date: Jul 2024 --> Oct 2025
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  NQO1 Mediates Lenvatinib Resistance by Regulating ROS-induced Apoptosis in Hepatocellular Carcinoma. (Pubmed Central) -  Feb 26, 2024   
    PD-1 inhibitor plus lenvatinib and Gemox are promising first-line regimens for the treatment of advanced BTC in the multicenter retrospective real-world study. The high NQO1 expression in HCC cells impedes the lenvatinib-induced apoptosis by regulating the ROS levels, thereby promoting lenvatinib resistance in HCC cells.
  • ||||||||||  AZD7003 / AstraZeneca
    Enrollment change, Trial completion date, Trial primary completion date, CAR T-Cell Therapy, Metastases:  A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Feb 26, 2024   
    P1,  N=48, Recruiting, 
    The high NQO1 expression in HCC cells impedes the lenvatinib-induced apoptosis by regulating the ROS levels, thereby promoting lenvatinib resistance in HCC cells. N=20 --> 48 | Trial completion date: May 2024 --> May 2041 | Trial primary completion date: Apr 2024 --> May 2026
  • ||||||||||  Review, Journal, Metastases:  Current Status and Future Direction in the Treatment of Advanced Adrenocortical Carcinoma. (Pubmed Central) -  Feb 21, 2024   
    There are also ongoing trials of combination treatments such as lenvatinib with pembrolizumab and cabozantinib with atezolizumab...Targeted therapies and immunotherapies, especially in combination regimens, are demonstrating potential and are the subject of continued research. The evolving genomic landscape emphasizes the significance of targeted therapies and the need for further in-depth studies to solidify effective treatment regimens for ACC.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Biomarker, Review, Journal:  Insights into lenvatinib resistance: mechanisms, potential biomarkers, and strategies to enhance sensitivity. (Pubmed Central) -  Feb 21, 2024   
    A series of recent researches have reported the mechanisms underlying the development of lenvatinib resistance in tumor therapy, which are related to the regulation of cell death or proliferation, histological transformation, metabolism, transport processes, and epigenetics. In this review, we aim to outline recent discoveries achieved in terms of the mechanisms and potential predictive biomarkers of lenvatinib resistance as well as to summarize untapped approaches available for improving the therapeutic efficacy of lenvatinib in patients with various types of cancers.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Tumor mutational burden:  Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma (clinicaltrials.gov) -  Feb 19, 2024   
    P2,  N=56, Recruiting, 
    Future studies are warranted to elucidate these associations. Trial completion date: Jan 2027 --> Mar 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial initiation date, Trial primary completion date, Combination therapy, Metastases:  Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC (clinicaltrials.gov) -  Feb 15, 2024   
    P1/2,  N=60, Recruiting, 
    Trial completion date: Jan 2027 --> Mar 2028 | Trial primary completion date: Jan 2026 --> Jan 2027 Initiation date: Apr 2023 --> Sep 2022 | Trial primary completion date: Nov 2023 --> Apr 2024
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  Neo PeLeMM: Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (clinicaltrials.gov) -  Feb 15, 2024   
    P2,  N=44, Not yet recruiting, 
    Initiation date: Apr 2023 --> Sep 2022 | Trial primary completion date: Nov 2023 --> Apr 2024 Trial completion date: Oct 2030 --> May 2036 | Trial primary completion date: Dec 2025 --> May 2026
  • ||||||||||  Enweida (envafolimab) / 3DMed, Ascletis
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors (clinicaltrials.gov) -  Feb 15, 2024   
    P1/2,  N=170, Recruiting, 
    Trial completion date: Oct 2030 --> May 2036 | Trial primary completion date: Dec 2025 --> May 2026 Trial completion date: Oct 2023 --> Jun 2024 | Trial primary completion date: Oct 2023 --> Jun 2024
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Metastases:  Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) -  Feb 15, 2024   
    P1,  N=11, Active, not recruiting, 
    Trial completion date: May 2028 --> Aug 2043 | Trial primary completion date: May 2028 --> Aug 2043 Trial completion date: Dec 2024 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Sep 2023